Eli Lilly Shares Rise on Positive Retatrutide Trial Data
Eli Lilly shares rose 4% after the company presented trial data for its next-generation obesity drug retatrutide. Analysts noted that a lower 4mg dose achieved weight loss comparable to current high-dose therapies while maintaining manageable side effects, potentially widening the gap with rivals.
Xurve View
Insights:
Xurve View
ELI LILLY & CO shares rose 4% on Monday afternoon following positive clinical trial data for its next-generation obesity treatment, retatrutide. The stock has gained 9% this year, while rival NOVO NORDISK A/S-B fell roughly 17% year-to-date. Investors view the drug as a catalyst to solidify ELI LILLY & CO dominance in a market projected to exceed $200 billion.
